This is also the first time that increased expression of the SS biomarker genes TIGIT and TOX have been associated with clinical progression of chronic L-HES to PTCL, supporting their roles in driving malignancy. This evidence concerns the gene TOX and mature T-cell and NK-cell non-Hodgkin lymphoma.